CRN04777 Given Rare Pediatric Disease Designation for Congenital Hyperinsulinism
source: pixabay.com

CRN04777 Given Rare Pediatric Disease Designation for Congenital Hyperinsulinism

  In a recent press release, clinical-stage pharmaceutical company Crinetics Pharmaceuticals announced that their investigational drug candidate, CRN04777, received Rare Pediatric Disease designation from the FDA. The therapy is designed…

Continue Reading CRN04777 Given Rare Pediatric Disease Designation for Congenital Hyperinsulinism
Positive Data Announced from AYVAKIT Clinical Trials for Systemic Mastocytosis
source: pixabay.com

Positive Data Announced from AYVAKIT Clinical Trials for Systemic Mastocytosis

  In a recent press release, precision therapy company Blueprint Medicines Corporation announced positive results from two clinical trials: EXPLORER and PATHFINDER. The trials examined the safety, efficacy, and tolerability…

Continue Reading Positive Data Announced from AYVAKIT Clinical Trials for Systemic Mastocytosis
Kevin Hart Gives a Hand to the Muscular Dystrophy Association As Host of the MDA Telethon
source: pixabay.com

Kevin Hart Gives a Hand to the Muscular Dystrophy Association As Host of the MDA Telethon

As sourced from BioSpace: After 44 years of the legendary Jerry Lewis hosting the Jerry Lewis MDA Telethon to bring awareness to this disorder, his tradition will live on in…

Continue Reading Kevin Hart Gives a Hand to the Muscular Dystrophy Association As Host of the MDA Telethon
EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment
source: pixabay.com

EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment

CRISPR Therapeutics, in combination with Vertex Pharmaceuticals, has recently announced that the European Medicines Agency (EMA) has granted the Priority Medicines (PRIME) designation for their sickle cell disease (SCD) treatment,…

Continue Reading EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment
Experimental Compound Shows Benefit in Mouse Model of Charcot-Marie-Tooth Disease Type 1A
source: pixabay.com

Experimental Compound Shows Benefit in Mouse Model of Charcot-Marie-Tooth Disease Type 1A

According to a story from Charcot-Marie-Tooth News, an experimental HDAC6 inhibitor called CKD-504 appeared to restore myelination in mouse and cell models of Charcot-Marie-Tooth disease type 1A in a recent…

Continue Reading Experimental Compound Shows Benefit in Mouse Model of Charcot-Marie-Tooth Disease Type 1A
Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
source: pixabay.com

Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases

  According to a recent article in Business Wire, it is estimated that five million people in the United States over the age of sixty-five are coping with Alzheimer’s at…

Continue Reading Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years
source: pixabay.com

Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years

  Dr. Richard Furie at New York’s Feinstein Institutes recently interviewed with MedPage Today. Dr. Furie discussed the prognosis for lupus nephritis and belimumab (Benlysta), a recently-tested drug that appears…

Continue Reading Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years
Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements
source: pixabay.com

Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements

  This year, thanks to COVID-19, many conferences have been held online. These play a crucial role in spreading data, facilitating conversations, and determining potential treatment options for patients with…

Continue Reading Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements